SCHEMBL5263328

SCHEMBL5263328

COc1ccc(-c2nc3nc(C)ccn3c2-c2ccc(OC)c(Cl)c2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.42
AKT1 P31749 2/20 0.42
AKT2 P31751 2/20 0.42
AURKB Q96GD4 2/20 0.42
INCENP Q9NQS7 2/20 0.42
MAPK14 Q16539 1/20 0.40
NPC1 O15118 4/20 0.39
RAB9A P51151 3/20 0.39
PPARD Q03181 1/20 0.39
TP53 P04637 2/20 0.38
POLB P06746 1/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
ALOX15 P16050 1/20 0.37
HPGD P15428 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5261621 0.89 AKT1 (0.41) AKT1AKT2MAPK14NPC1RAB9A
SCHEMBL5803806 0.88 AKT1 (0.41) SYKAKT1AKT2AURKBINCENP
SCHEMBL5260224 0.87 AKT1 (0.41) SYKAKT1AKT2AURKBINCENP
SCHEMBL5265348 0.86 AKT1 (0.38) AKT1AKT2MAPK14NPC1RAB9A
SCHEMBL5263776 0.85 HSP90AA1 (0.41) AKT1AKT2MAPK14NPC1ALDH1A1
SCHEMBL5261963 0.84 AKT1 (0.39) SYKAKT1AKT2AURKBINCENP
SCHEMBL5262639 0.83 AKT1 (0.36) AKT1AKT2MAPK14NPC1RAB9A
SCHEMBL5267924 0.83 MAPK14 (0.41) SYKAKT1AKT2AURKBINCENP
SCHEMBL5262769 0.83 AKT1 (0.40) SYKAKT1AKT2AURKBINCENP
SCHEMBL5267408 0.83 AKT1 (0.38) SYKAKT1AKT2AURKBINCENP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1660500-B1 SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER S A L V A T LAB SA (ES) 2007-12-12 EP disclosed
US-20060189631-A1 Substituted imidazopyrimidines for the prevention and treatment of cancer LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189631-A1 Substituted imidazopyrimidines for the prevention and treatment of cancer BRCA1, CCNA1, DPYD SYK 4083/4885AKT1 3579/4885AKT2 3297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.